- Report
- August 2025
- 199 Pages
Global
From €3112EUR$3,545USD£2,707GBP
€3458EUR$3,939USD£3,008GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- August 2025
- 194 Pages
Global
From €3112EUR$3,545USD£2,707GBP
€3458EUR$3,939USD£3,008GBP
- Report
- January 2024
- 95 Pages
Global
From €3500EUR$4,271USD£3,151GBP
- Report
- September 2025
- 50 Pages
Global
From €2327EUR$2,650USD£2,024GBP
- Report
- September 2025
- 50 Pages
Global
From €2327EUR$2,650USD£2,024GBP
Vindesine is an oncology drug used to treat a variety of cancers, including breast, ovarian, and lung cancer. It is a semi-synthetic vinca alkaloid, derived from the Madagascar periwinkle plant, and works by inhibiting the growth of cancer cells. Vindesine is typically administered intravenously, and is often used in combination with other chemotherapy drugs.
Vindesine is available in many countries around the world, and is marketed by a number of pharmaceutical companies. It is typically prescribed by oncologists, and is available in both generic and branded forms.
Companies in the Vindesine market include Pfizer, Novartis, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more